STUDY OF PYRAZOLOACRIDINE FOR TREATMENT OF HORMONE REFRACTORY PROSTATE CANCER

吡唑吖啶治疗激素难治性前列腺癌的研究

• 批准号: 6246365
• 负责人: ERIC J SMALL
• 金额: $ 4.89万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-04 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246365
• 关键词: acridines; antineoplastics; clinical research; drug adverse effect; human old age (65+); human subject; human therapy evaluation; male; neoplasm /cancer chemotherapy; neoplasm /cancer remission /regression; pain; pharmacokinetics; prostate neoplasms; prostate specific antigen; quality of life; questionnaires

We propose to evaluate the efficacy of PZ in treatment of hormone refractory prostate cancer. Objectives are: to evaluate response rate of pts with chemotherapy naive cancer by changes in PSA and other measurments of disease activity when treated with PZ. To evaluate impact of quality of life and pain control using questionnaires. To describe toxicity profile of PZ in a uniform, older patient population. To describe overall and progression free survival. To describe population pharmacokinetic variable.

我们建议评估 PZ 治疗激素的疗效 难治性前列腺癌。 目标是：评估响应率 通过 PSA 和其他指标的变化来评估未接受过化疗的癌症患者 用 PZ 治疗时疾病活动度的测量。 评估影响 使用问卷调查来评估生活质量和疼痛控制。 来描述 PZ 在统一的老年患者群体中的毒性特征。 到 描述总体生存期和无进展生存期。描述人口 药代动力学变量。